Media center

We provide ongoing updates on our commercial, clinical and financial progress through regular press releases, presentations and webcasts, which can be accessed through the company’s media center.

Press Releases

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

Click here to download full press release – PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR),...

Circassia Announces Submission of Duaklir® New Drug Application and Tudorza® Supplemental New Drug Application in the United States

Click here to download full press release – Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) – – Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label –...

Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies

Click here to download full press release Oxford, UK – 22 May 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of...
More press releases

In this section

Press releases

Presentations

Webcasts & audio

Image library

Media contacts